We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Allogene Therapeutics (ALLO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Allogene Therapeutics is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ALLO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 4.16% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ALLO has moved about 0.31% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.70%. This shows that Allogene Therapeutics is outperforming its peers so far this year.
To break things down more, ALLO belongs to the Medical - Biomedical and Genetics industry, a group that includes 384 individual companies and currently sits at #20 in the Zacks Industry Rank. Stocks in this group have lost about 1.93% so far this year, so ALLO is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ALLO. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Allogene Therapeutics (ALLO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Allogene Therapeutics is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ALLO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 4.16% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ALLO has moved about 0.31% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.70%. This shows that Allogene Therapeutics is outperforming its peers so far this year.
To break things down more, ALLO belongs to the Medical - Biomedical and Genetics industry, a group that includes 384 individual companies and currently sits at #20 in the Zacks Industry Rank. Stocks in this group have lost about 1.93% so far this year, so ALLO is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ALLO. The stock will be looking to continue its solid performance.